1. Chen YT, Burchell A. Glycogen storage diseases.
In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic
and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill;
2001:1521-1552.
2. Kim SY, Weinstein DA, Starost MF, Mansfield BC, Chou JY.
Necrotic foci, elevated chemokines and infiltrating neutrophils
in the liver of glycogen storage disease type Ia. J Hepatol. 2008;48(3):479-485.
3. Rake JP, ten Berge AM, Visser G, et al. Glycogen storage
disease type Ia: recent experience with mutation analysis, a summary
of mutations reported in the literature and a newly developed diagnostic
flow chart. Eur J Pediatr. 2000;159(5):322-330.
4. Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular
carcinoma in glycogen storage disease type Ia: a case series. J
Inherited Metab Dis. 2005;28(2):153-162.
5. Demo E, Frush D, Gottfried M, et al. Glycogen storage disease
type III-hepatocellular carcinoma a long-term complication? J
Hepatol. 2007;46(3):492-498.
6. Shen JJ, Chen YT. Molecular characterization of glycogen
storage disease type III. Curr Mol Med. 2002;2(2):167-175.
7. Endo Y, Horinishi A, Vorgerd M, et al. Molecular analysis
of the AGL gene: heterogeneity of mutations in patients with glycogen
storage disease type III from Germany, Canada, Afghanistan, Iran,
and Turkey. J Hum Genet. 2006;51(11):958-963.
8. Bruno C, van Diggelen OP, Cassandrini D, et al. Clinical
and genetic heterogeneity of branching enzyme deficiency (glycogenosis
type IV). Neurology. 2004;63(6):1053-1058.
9. Moses SW, Parvari R. The variable presentations of glycogen
storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr
Mol Med. 2002;2(2):177-188.
10. Bao Y, Kishnani P, Wu JY, Chen YT. Hepatic and neuromuscular
forms of glycogen storage disease type IV caused by mutations in
the same glycogen-branching enzyme gene. J Clin Invest. 1996;97(4):941-948.
11. Beauchamp NJ, Taybert J, Champion MP, et al. High frequency
of missense mutations in glycogen storage disease type VI. J
Inherited Metab Dis. 2007;30(5):722-734.
12. Burwinkel B, Rootwelt T, Kvittingen EA, Chakraborty PK,
Kilimann MW. Severe phenotype of phosphorylase kinase-deficient
liver glycogenosis with mutations in the PHKG2 gene. Pediatr
Res. 2003;54(6):834-839.
13. Burwinkel B, Hu B, Schroers A, et al. Muscle glycogenosis
with low phosphorylase kinase activity: Mutations in PHKA1, PHKG1
or six other candidate genes explain only a minority of cases. Eur
J Hum Genet. 2003;11(7):516-526.
14. Burwinkel B, Scott JW, Buhrer C, et al. Fatal congenital
heart glycogenosis caused by a recurrent activating R531Q mutation
in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2),
not by phosphorylase kinase deficiency. Am J Hum Genet. 2005;76(6):1034-1049.
15. Fukao T, Zhang G, Aoki Y, et al. Identification of Alu-mediated,
large deletion-spanning introns 19-26 in PHKA2 in a patient with
X-linked liver glycogenosis (hepatic phosphorylase kinase deficiency). Mol
Genet Metab. 2007;92(1-2):179-182.
16. Beauchamp NJ, Dalton A, Ramaswami U, et al. Glycogen storage
disease type IX: high variability in clinical phenotype. Mol
Genet Metab. 2007;92(1-2):88-99.
17. Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI. Hepatic
glycogen synthase deficiency: an infrequently recognized cause of
ketotic hypoglycemia. Mol Genet Metab. 2006;87(4):284-288.
18. Pascual JM, Wang D, Lecumberri B, et al. GLUT1 deficiency
and other glucose transporter diseases. Eur J Endocrinol. 2004;150(5):627-633.
19. Gordon N. Glycogenosis type V or McArdle’s disease. Dev
Med Child Neurol. 2003;45(9):640-644.
20. Deschauer M, Morgenroth A, Joshi PR, et al. Analysis of
spectrum and frequencies of mutations in McArdle disease. Identification
of 13 novel mutations. J Neurol. 2007;254(6):797-802.
21. Haller RG, Vissing J. Spontaneous “second wind” and
glucose-induced second “second wind” in McArdle
disease: oxidative mechanisms. Arch Neurol. 2002;59(9):1395-1402.
22. Martinuzzi A, Liava A, Trevisi E, et al. Randomized, placebo-controlled,
double-blind pilot trial of ramipril in McArdle’s disease. Muscle Nerve. 2008;37(3):350-357.
23. Kishnani PS, Howell RR. Pompe disease in infants and children. J
Pediatr. 2004;144(Suppl 5):S35-S43.
24. Hirschhorn R, Reuser AJJ. Glycogen storage disease type
II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver
CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Molecular
Bases of Inherited Disease. 8th ed. New York: McGraw-Hill;
2001:3389-3420.
25. Winchester B, Bali D, Bodamer OA, et al. Methods for a prompt
and reliable laboratory diagnosis of Pompe disease: report from
an international consensus meeting. Mol Genet Metab. 2008;93(3):275-281.
26. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster
ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset
Pompe disease. J Pediatr. 2006;149(1):89-97.
27. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy
and exercise intolerance in muscle glycogen storage disease 0. N
Engl J Med. 2007;357(15):1507-1514.
28. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases
presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362-372.